Proton & Carbon Ion Radiation Therapy & Precision Brachytherapy

Radiation Frontier · Bragg Peak Precision

国家甲类大型医用设备准入配置许可 · Top-tier Particle Radiation Technology / Bragg-Peak Stereotactic Therapy

The gold standard in radiation oncology. Accelerated to 70% of the speed of light, proton and carbon ion beams deposit minimal entry dose until stopping precisely at the tumor target depth to release their maximum lethal destructive energy (the Bragg Peak), sparing surrounding vital structures.

5-Year Local Control (Chordoma / Prostate)

85.0% - 93.5%

Control: 50-65%

Evidence Level

National Health Commission Particle Therapy Criteria / ASTRO Clinical Model

Shanghai Proton and Heavy Ion Center (SPHIC) & ASTRO

Treatment Course

3-5 天

15-30 fractions over 3-5 weeks. Non-invasive, painless outpatient procedure.

Global Advantage

Save ~70%

Direct Billing Available

Mechanism of Action (MOA)

Bragg Peak Physics: Maximum Lethal Dose with Zero Exit Damage

1

Bragg Peak Physics: Minimal entry radiation followed by explosive energy deposit exclusively inside the target tumor.

2

Zero Exit Dose: Energy drops to absolute zero beyond the tumor boundary, shielding vital healthy tissues behind.

3

High Biological Effectiveness (RBE): Carbon ions exert 2-3x higher biological kill rate, cleaving clustered double-strand DNA.

4

Childhood Development Preservation: Sparing normal tissues drastically reduces secondary malignancies and developmental deficits.

Patient Profile & Indications

Quantified entry criteria and stages for foreign referral

Skull Base & CNS Tumors: Chordoma, chondrosarcoma, meningioma, and acoustic neuroma.

Pediatric Solid Tumors: Medulloblastoma, neuroblastoma, and rhabdomyosarcoma.

Deep Visceral Tumors: Prostate cancer, early NSCLC, hepatocellular carcinoma, pancreatic cancer, and ACC.

Strict Exclusion Red Lines

• ✕Widespread metastatic disease (>3-5 disseminated lesions with poor systemic control).
• ✕Hollow organ tumors (esophagus, stomach) at risk of immediate perforation.
• ✕Exceeded cumulative tissue tolerance from prior overlapping radiation.

Clinical Trial Data & Real-World Outcomes

Shanghai Proton and Heavy Ion Center 10-Year Clinical Register Cohort (5000+ Cases)

5-Year Local Control (Chordoma / Prostate)

85.0% - 93.5%

Disease Control (DCR)

95.0%

Evidence Grade

National Health Commission Particle Therapy Criteria

Safety Profile: Severe radiation toxicity reduced by >70% vs photons; non-invasive outpatient treatment with minimal fatigue.

Official Regulatory Registries & Authoritative Sources

Direct verification links to NMPA, ClinicalTrials.gov, PubMed and CSCO/FDA registries

National Class-A

China NHC & NMPA Class-A Particle Therapy System Certification

ASTRO Clinical Policy

ASTRO Model Policies for Proton Beam Therapy

PubMed Indexed

PubMed: Long-term Outcomes of Carbon Ion Radiotherapy in Lancet Oncology

Benchmark Hospital Centers

World-leading Dual-Beam Proton/Carbon Ion Center (>6,000 Cases)

Shanghai Proton and Heavy Ion Center (SPHIC)

Department of Radiation Oncology / Medical Physics Center

Prof. Jiang Guoliang & Prof. Lu Jiade Clinical MDT

National Particle Therapy Center Led by Academician

Shandong Cancer Hospital (Proton Clinical Center)

Radiation Oncology / Proton Center

Academician Yu Jinming Clinical MDT

Required Medical Records:

•Original histopathology biopsy report.

•High-resolution thin-slice (<=1.5mm) enhanced CT and 3.0T MRI DICOM within 14 days.

•Prior radiation DVH and field reports (if applicable) to evaluate cumulative dose.

•Whole-body PET-CT scan ruling out distant widespread dissemination.